Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person12
Vaxcyte, Inc.
Company
MAXCYTE, INC.
Company
VERACYTE, INC.
Company
Vaxart, Inc.
Company
Humacyte, Inc.
Company
INCYTE CORP
Company
V2X, Inc.
Company
VALHI INC /DE/
Company
Visa Inc
Company
VERU INC.
Company
VEEA INC.
Company
VALVOLINE INC
Company
Primary record18
T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A
0001897612-26-000705.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001897612-25-000545 0001897612 XXXXXXXX LIVE 3 COMMON STOCK 10/31/2026 0001649094 VAXCYTE INC 92243G108 825 INDUSTRIAL ROAD STE.
T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A
0001897612-26-000700.txt : 20261106 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001897612-25-000545 0001897612 XXXXXXXX LIVE 2 COMMON STOCK 09/30/2026 0001649094 VAXCYTE INC 92243G108 825 INDUSTRIAL ROAD STE.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-11-04.
Vaxcyte, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press rel
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-11-04.
Vaxcyte, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On October 9, 2026, Vaxcyte, Inc. ( Vaxcyte ) consummated the sale and issuance of $575,000,000 aggregate principal amount of its 1.50% Convertible Senior Notes due 2
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-10-07.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-10-07.
Vaxcyte, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On October 5, 2026, Vaxcyte, Inc. (the Company ) issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerabilit
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-10-02.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-09.
Vaxcyte, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 31, 2026, Vaxcyte, Inc. (the “Company”) appointed Da
Vaxcyte, Inc. filed 4
SEC form 4 filed by Vaxcyte, Inc. (CIK 1649094) on 2026-09-02.